Trump to visit Fed on Thursday amid Powell feud, renovation probe
Sleep Cycle AB released its Q1 2025 earnings report, revealing a modest increase in revenue but a significant drop in stock value. The company’s net revenue reached SEK 64.9 million, marking a 2.3% year-over-year growth, while the stock price fell by 16.38% to SEK 34.2. According to InvestingPro data, the company maintains strong fundamentals with a "GREAT" overall financial health score and holds more cash than debt on its balance sheet. Despite the revenue growth, the stock’s decline reflects investor concerns over future prospects.
Key Takeaways
- Net revenue increased by 2.3% year-over-year.
- Stock price dropped by 16.38% following the earnings report.
- Subscriptions grew to 904,000, a 1.2% year-over-year increase.
- Average Revenue Per User (ARPU) saw a slight decrease of 1.5%.
- Sleep Cycle is investing in new technologies and platform expansion.
Company Performance
Sleep Cycle’s performance in Q1 2025 showed resilience in revenue growth amidst a challenging market environment. The company reported SEK 64.9 million in net revenue, a 2.3% increase from the previous year. The number of subscriptions rose to 904,000, representing a 1.2% increase, although ARPU experienced a slight decline to 272 SEK. Despite these positive indicators, the broader sleep health app segment is witnessing a decline in downloads, affecting market sentiment.
Financial Highlights
- Revenue: SEK 64.9 million, up 2.3% year-over-year
- EBIT: SEK 17.1 million, with a 26.3% margin
- Subscriptions: 904,000, up 1.2% year-over-year
- ARPU: 272 SEK, down 1.5%
- Liquidity: SEK 157 million at the end of the quarter
Market Reaction
Following the earnings release, Sleep Cycle’s stock dropped by 16.38%, closing at SEK 34.2. This decline places the stock closer to its 52-week low of SEK 32.3, significantly below the 52-week high of SEK 49.4. InvestingPro analysis suggests the stock is currently undervalued, with an attractive P/E ratio of 14.7x and a significant dividend yield of 7.33%. The stock’s sharp decline reflects investor apprehension, possibly due to the company’s cautious outlook and the overall downturn in the sleep health app market. For detailed valuation metrics and 6 additional ProTips, visit InvestingPro.
Outlook & Guidance
Sleep Cycle remains committed to its long-term financial targets and is exploring new avenues for growth. The company’s strong financial position is evidenced by its impressive 56.96% gross margin and 89% return on equity, as reported by InvestingPro. The company is developing sleep apnea screening technology and plans to launch clinical trials in Q2 2025. However, no revenue from sleep apnea is expected in 2025. The company is also expanding its technology platform, including a new web platform aimed at improving web-to-app conversions.
Executive Commentary
CEO Eric Giemarck emphasized Sleep Cycle’s leadership in the sleep technology space, stating, "We are the world’s leading sleep technology company." He highlighted the growing importance of sleep as a broader topic and the company’s ambition to leverage its platform for future growth. Giemarck also mentioned, "We’re not only looking to use our platform and technology to power others, but also our own future."
Risks and Challenges
- Declining downloads in the sleep health app segment could impact growth.
- Currency fluctuations, with 40% of revenue generated in US Dollars, pose a risk.
- Competition in the market remains intense, with significant download drops.
- The success of new technology initiatives, such as sleep apnea screening, is uncertain.
- Managing marketing spend and customer acquisition costs is crucial for maintaining profitability.
Q&A
During the earnings call, analysts inquired about Sleep Cycle’s strategies for product improvement and technology platform expansion. The company is investigating the potential of the sleep apnea market and monitoring marketing expenditures closely. Analysts also explored partnership opportunities that Sleep Cycle might pursue to enhance its market position.
Full transcript - Sleep Cycle AB (SLEEP) Q1 2025:
Eric Giemarck, CEO, Sleep Cycle: and welcome. Today, we’re sharing the interim report for quarter one. My name is Eric Giemarck. I’m the CEO at Sleep Cycle. And with me, I have Elisabeth Hiedmann, our CFO and head of investor relations.
We are Sleep Cycle. We are the world’s leading sleep technology company. We have a mission to improve global health by helping people to take control of their sleep. We are used and loved by millions and available in more than 50 markets, in app stores, and as part of many wearables. At the core, our app help people build healthy sleep habits, something that is more needed than ever.
What set us apart is that we’re not just the world’s largest sleep app. We have a proprietary technology platform as well. Everything we do, from sleep tracking and smart alarms to audio features like sleep aids, snore detection, and sleep talking recording helps users understand and improve their sleep. And it’s all built on proprietary audio and sleep science technology, engaging and powered by science. There’s a lot of uncertainty in the world right now, and the macroeconomic pressure is impacting markets across the board.
During Q1, we saw a continued downward trend among many of our peers in terms of downloads. This isn’t new. We already saw signs of this in q four as shared at our year end call. And while we’re still growing our subscriber base year over year, which shows our relevance and resilience, we are also impacted. The slowdown has also continued into April.
Now despite the drop in downloads, which is affecting the entire industry, and as I said, many of our competitors are down much more, there are some bright spots. Our brand has a strong presence and what I often said before, a true market fit. And we see that our conversion rates and annual renewal rates are steady. That tells us that the users who do come in are highly engaged and sticking with us. Also, we have to remember, even though the sleep segment is down in the App Store right now, the societal interest for sleep has never been greater.
That’s why we’re doubling down on expanding beyond the app. We stand by our financial targets, but it will not be a linear journey. So we’ve continued to gain market share in a tough quarter. That’s a direct result of our focus on what we can control, like onboarding and win back strategies, which are paying off. Churn is going down.
We see that the release of sleep stages in December have improved data reliability, which was a strategic bet for decreasing churn. We’re truly focusing on what we can control, and the team is doing it well. We’re currently growing faster than our competitors, and that momentum is fueled by organic loops and a stronger brand presence, and we are only down around 10% in new downloads. This is thanks to our true product market fit. We see that some competitors relying heavily on paid media and less on product development are down massively.
Our efforts regarding new customers are taking shape with the newly formed team as well as the launch of our refreshed brand. On the partnership side, we have renewed our agreement with Wellhub under much better terms, locking in a guaranteed revenue for several years. Our collaboration with Revolut is also progressing well. MyFitnessPal, on the other hand, was something we were clear about that we didn’t really know what to expect given the new way of partnering and also the underlying technology. But we can conclude that it has not performed, and we’re closely evaluating the next steps there.
So sleep and its benefits are as relevant as ever. Our basic human needs haven’t shifted. People still need quality sleep to function, to focus and to feel well. If anything, the demand is growing. But what we see is that sleep is also being consumed outside of pure sleep apps.
This represents both a challenge and an opportunity. It’s pushing us to think more broadly about how and where our technology can add value. This is why Powered by Sleep Cycle was born. At the core of everything we do is our AI sound model. It’s developed in house, it’s trained on over 3,000,000,000 nights of sleep, and it’s continuously evolving.
This technology is what powers the world’s number one sleep app. But it’s so much more than that. I mean, it generates unique data insights, it enables smart features like full sleep staging and snore detection, and it creates real value for users night after night. But we’re no longer keeping that power just inside the app. With Power by Sleep Cycle, we are opening up our technology to the world.
That means others can license our SDK and integrate it into their own products and services, whether it’s wellness, health care, wearables, or even physical products. So whether it’s enriching our own app, unlocking new revenue streams through data and integrations, or addressing global health challenges, this platform is designed to scale. We currently have multiple discussions underway with potential partners who are interested exploring these kinds of integrations. These conversations are, of course, also helping us shaping our offering. However, we’re not only looking to use our platform and technology to power others, but also our own future.
Sleep apnea is a massive global health issue and still dramatically underdiagnosed. Our technology and also the ability to understand breathing gives us a unique opportunity to address this at scale, directly from the phone. We’re now starting the process for medical certification. It’s a big step forward. It’s still early days, but if successful, Sleep Cycle could become the first FDA and CE approved app for large scale sleep apnea screening.
Of course, a medical certification will also help us in many of the partnership dialogues and build increased trust in our product also outside sleep apnea. We’re confident in our technology and in the value it can bring. The potential market is big and the need is real. Our goal is to kick off the clinical trials in quarter two, marking the beginning of a long term opportunity to help millions of people sleep and live better. And with that, I’m handing over to Elisabeth to take us through the financial developments for Q1.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Thank you, Eric. Let’s begin with a summary of the quarter’s key financial metrics. On the subscription side, we reached nine zero four subscriptions, which is up 1.2% year over year, but it is a decrease compared to last quarter. The ARPU amounted to 272 SEK, representing a slight year over year decrease of 1.5%, mainly driven by weaker new sales that is also negatively affected by the weaker US dollar and efforts to convert free users to paying subscribers. We have had more customers coming in at a lower ARPU.
During the first quarter, we we recorded a 2.3% year over year increase in net revenue, reaching SEK 64,900,000.0. And the EBIT came in at SEK 17,100,000.0, corresponding to a solid EBIT margin of 26.3%, a reflection of continued cost discipline and operational efficiency. Despite some short term headwinds, the long term development has been stable, and we’re staying on course. The number of paying subscribers decreased with 14,000 during the quarter, but it’s still 11,000 higher than last year, reaching 904,000. While we faced around 10% fewer downloads compared to q one last year, driven by the tougher market conditions, both our conversion rate and renewal rate remained steady.
In a volatile market environment, we’re strengthening our position and gaining market share as we see that competitors are hit even harder. This demonstrates the underlying strength of our product and our ability to retain and engage the users over time. Net sales totaled at 64,900,000.0, and the growth rate for the quarter was somewhat impacted by a lower ARPU and a lower sales to new customers, but we are maintaining our long term growth trajectory and strong margins. Let’s move on to profitability. As previously mentioned, we reported an EBIT of SEK 17,100,000.0 for the quarter, which corresponds to 26.3% EBIT margin.
It’s a solid result. The margin is slightly down compared to previous quarters as and that’s mainly due to higher marketing costs and some additional investments we’ve made to explore new revenue streams, intentional steps aligned with our long term strategy. If we look at the adjusted EBIT excluding nonrecurring items, our margin has stayed above 25% for five quarters in a row. For this quarter, we did not have any nonrecurring items. Before diving into the P and L for the quarter, I want to take a moment to highlight the impact of currency fluctuations that we have seen more of recently.
Around 40% of our revenue is generated in U. S. Dollars. When the Swedish krona strengthens against the dollar, it reduces the SEK value of those sales. Since much of our revenue is recognized over a twelve month period, the figures for this quarter reflect sales and exchange rates over the past year.
If the current FX trends and softer market conditions persist, they may continue to affect revenue development going forward. We’re also affected by FX in another way. Although the majority of our sales is made in foreign currencies, the payments we receive from platforms like Apple are settled in Swedish kronor. There’s a delay of up to two months between the time of sales and the time of payments. And if exchange rates shift during that period, it impacts the value of our transactions when it’s recorded and internal profit.
We did, however, record a net revenue growth of 2.3% or 1.6% currency adjusted. And the net revenue growth was driven by a higher number of paying subscribers compared to previous year and successful partnerships, although ARPA declined slightly due to a lower intake of new customers as well as our strategic freemium and win back campaigns. On the cost side, we had slightly lower distribution costs, thanks to a more favorable mix between new and renewed subscriptions. And the other external costs increased by 19.7%, somewhat due to higher marketing spend, in line with our plan to support future growth. Note that last year’s figure included NRIs of 800,000 SEK.
The staff costs were lower compared to q one last year, but that’s explained by nonrecurring items in q one twenty twenty four of 5,000,000 SEK related to the reorganization and consolidation of offices. And the average number of employees were 33 during q one this year compared to 37 last year. Depreciation and amortization also decreased mainly since the previous year’s figure included the lease for two offices, both one in Gothenburg and one in Stockholm. Now we only have one. The other operating expenses include negative FX effects of SEK 1,300,000.0 related to the time gap between point of sales and point of payment from Apple.
Normally, these impacts are fairly limited, but due to the recent volatility in the U. S. Dollars and other currencies, the effect was more pronounced this quarter. The EBIT margin of 26.3% is in line with our long term target of at least 25% annually. Finally, our liquidity remains strong at 157,000,000 at the end of the quarter.
Now over to you, Erik, to wrap it up.
Eric Giemarck, CEO, Sleep Cycle: Thanks, Elizabeth. So our new strategy was designed with this in mind, and we stand firm by our financial targets. We’re focusing on upper funnel. We’re bringing product improvements to the app, and we see the results with decreasing churn and also new possibilities. We are taking market shares, and we’re also accelerating our future bets, opening up our technology to the world with Powered by Sleep Cycle.
I’m really looking forward to see how the new bets will materialize, capturing the general interest around sleep and the growth beyond our current market reach. Thank you for your continued trust and support. And with that, we are happy to take the questions you might have.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Alright. First, we we have a question regarding what the main focus from management is to achieve the financial targets to increase their revenue since subscribers have been flat for the last years. Do you wanna elaborate on that one, Eric?
Eric Giemarck, CEO, Sleep Cycle: Yeah. So the the strategy speaks about a couple of things. One is the the upper funnel. And and in this quarter, we have invested in a dedicated team working more diligently with the upper funnel activities. And I think that is part of the reason why we are also seeing that we can take market shares in in the current market.
The other thing is obviously that we’re continuing to investing in the product. We are a product company, and we see that when we make the right investments, such as sleep staging and allowing us to be able to track breathing, it also helps our renewal rate, mitigating churn. The third thing, which is one of the the bigger things that we talked about today, is is the fact that we are opening up our technology platform. So what has made us the most successful sleep app in the world, that underlying proprietary technology is now something that we are opening up to to partners to be able to to leverage and to build either integrating their current experiences or to build on top. I mean, we are an authority within sleep science, but also sleep technology.
So we’re starting the discussions with some very well known brands across relevant segments, but but also devices, And we we have high hopes on that. All of this, we believe, will help us to generate the growth that we have set out in the financial targets.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Then there’s a question regarding if we can elaborate on the item capitalized work for own account in the p and l and why it differs from the line in the cash flow statement. What we have in the p and l is the work from our own staff. So it’s 400,000 siek capitalized from our own staff. The difference between that one and the one the figure 3,800,000 in the cash flow statement is external costs. Currently, we have three projects that we are capitalizing on.
One is obviously sleep apnea. That is the main project. We’re also we have also launched a new web that will improve the web to app process and hopefully leading to more customers joining us from the web instead of through the app stores. We have also we’re working working on Coffrater site that will show and visualize our data that we possess.
Eric Giemarck, CEO, Sleep Cycle: What would be a realistic timeline for the sleep apnea certification? Well, as you know, getting a a medical approval, it’s going through some different steps. So for us, this is a mid to long term effort. And we are currently progressing through all the regulatory process. We have had meetings with some regulatory bodies, and it’s on the back of those meetings that we have decided to start our clinical trial now in the second quarter.
So after that, we will after we see the outcome of the clinical trial, that’s when we will decide to go for the formal application or not.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Yes. And then we have a question also regarding the sleep apnea project, what the cost will be per quarter. And I as I previously mentioned, we are capitalized this as we see it as quite the quite an investment for us. The amounts that will be invested will differ from quarter to quarter. We will be working on this the full year and somewhat into next year as well.
Eric Giemarck, CEO, Sleep Cycle: We also got a question on the marketing. You previously said you’re waiting to finding traction before starting increasing in marketing. Why did you start to increase in marketing? We see traction in marketing. That’s why we have started to increase the spend.
So we’re always keeping a close eye on on cost per install, cost per trial, but also the CAC LTV. So as soon as we see that, that’s when we started to invest. I think we’re still investing moderately. You see you mentioned in the CEO letter that the sleep health segment has seen a decline in the App Store. Could you elaborate on your thoughts on the key drivers in this trend?
Well, I think, first of all, we have to remember that health is is is a super popular and growing category. I mean, it it’s very clear that people are willing to invest in their well-being. What part of health we’re willing to invest in shift over time, and we see right now, which we believe is temporary and probably also connected to some of the uncertainty in the world, that, you know, our peers and our segment is is slightly down. But it also make us aware that, you know, we need to be able to keep more than one thing in our head at the same time. We we can focus on our app business, which we have done during the quarter.
We have taken market shares, but we also need to diversify and and broadening our offers with powered by Sleep Cycle, selling the technology, but also building new products on top of our technology, such as sleep apnea. So sleep as a topic, it’s growing, and and we need to think about it more more broadly.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Then we have another question regarding FX, how we should think about that going forward, particularly in the light of the recent CX strength and how balanced is our FX profile in terms of revenues and costs. Our main the majority of our costs are in Swedish kronor. And as I said, we get our payments in Swedish kronors as well. So the the FX translation is made on the partnership side. Obviously, we are looking at what we can do to to make the effects smaller.
Eric Giemarck, CEO, Sleep Cycle: We have a question around 80% of new users comes from recommendation. Does it include recommendation from app stores? Yes. I mean, 80% of our new users are organic, and that could come through word-of-mouth, but also the fact that we are organically surfaced by app stores. So so it’s it’s both.
Any other questions? Any measurable effects in customer acquisition retention of the new branding launched in March? So we haven’t rolled it out to current users yet, so it’s it’s too early to say. We have obviously done tests on the current user base. We launched it during the the later part of March for for new users, and we rolled it out gradually.
We see some promising sign in terms of onboarding and conversion rates. But since we went live fairly late in March, it’s too early to to draw any significant conclusions.
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: Alright. We have a question regarding how we work with the excess of cash. If we focus on receiving a good interest rate from the bank, yes, obviously, we do have a large cash at our hand, and we work with with banks to make sure that we get get the best interest we we can given given our strategy for it. There’s also a question regarding buybacks and why it’s not used as a tool. This is something that that that is a question for the board and the AGM, of course.
I know it has been looked into. And during due to the lower liquidity in the share as well as the way the cap table looks, it was was deemed to be a better solution to give a higher divi dividend this year at least.
Eric Giemarck, CEO, Sleep Cycle: We have a question about the E and PS. So my view is that people at Sleep Cycle are are are quite happy to be here. We have to remember that we have done quite significant changes during the last year. And, of course, being a small team, that impacts that that impacts the the feelings that that people have. But I I feel we’re in a good place as a team, and we are aligned on on the things we we are achieving going forward.
We got a question on the medical certification for sleep apnea screening. How do you expect this to influence your commercial strategy and revenue model? I think it’s it’s too early to say. We will come back on on the the revenue assumptions that we that we’ve made. Obviously, we have a a strong business case in the background.
That that’s the reason why we we we’re investing in this. At the same time, we will conduct some tests in parallel. So we’re we’re doing that already now with users where we do fake door tests, etcetera, to to see click through rates and so forth. But we don’t expect any sales or revenue connected to sleep apnea in 2025. Could you comment on subscriber retention and churn during the quarter?
Yeah. Both subscriber retention or or churn developed positively during the quarter. And and, again, I I think that speaks about the fact that the the product we have is loved. The the the challenge is that right now, the last couple of months, it has been fewer people in the upper funnel. So that is the the reason why we where we saw a bit of a decline in in q one.
But, again, our product stands strong compared to to the competitors. And and we are also, of course, converting a lot of new people. But there are fewer people in the funnel right now, and that’s what we’re act actively working with to ensure that we convert as many of them as possible and also broadening our reach through the partnership strategies, etcetera. When you now found traction in marketing, when do you expect to return to growth? Is it necessary for the market to turn before you can grow again?
No, I don’t think we need the market to to turn. I think we’re in charge of our own destiny. I think we’ve again, we’ve proven that during the quarter, we’ve been growing or taking market shares quite significantly. So I I I don’t see that as as being the the the problem. Good.
So thank you very much, everyone, for the questions and for listening in. As I said, we have an exciting quarter ahead of us. We are putting a lot of new things in the market, both short term to make sure that we continue to take the market shares and that we can continue to grow. But also, we’re putting in quite some substantial efforts in the medium to long term bets that we have. And I’m I’m really excited to see how these will start to materialize during the next couple of months.
Thank you, everyone. Thank you
Elisabeth Hiedmann, CFO and Head of Investor Relations, Sleep Cycle: so much. Bye.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.